https://powerbase.info/api.php?action=feedcontributions&feedformat=atom&user=Hmu05654Powerbase - User contributions [en]2026-06-25T18:33:47ZUser contributionsMediaWiki 1.35.14https://powerbase.info/index.php?title=Henry_A._McKinnell,_Jr.&diff=23988Henry A. McKinnell, Jr.2006-04-26T18:59:03Z<p>Hmu05654: </p>
<hr />
<div>"Dr. Henry A. McKinnell Jr. became chief executive officer of [[Pfizer]] in January 2001 and chairman of the board in April 2001 after holding a series of senior executive positions spanning more than 32 years with the company. During his time at Pfizer, McKinnell helped turn the company from a leader in the pharmaceutical industry into a "transforming force" with the acquisitions of Warner-Lambert in 2000 and Pharmacia in 2003 and the subsequent successful integration of both firms, forming a behemoth that earned $45 billion in 2003. Observers described McKinnell as polished, stately, and avuncular, yet also exacting, passionate, and sometimes impatient." [http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html]<br />
<br />
He is also chairman of the Governance and Compensation Committee and is a member of the Audit Committee of the Board of Directors. [http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=mco&script=2220&item_id=46518]<br />
<br />
Since 2002, he is a member of the Board of Directors [http://www.exxonmobil.com/Corporate/InvestorInfo/Corp_II_Board.asp] of [[ExxonMobil]], the world's largest integrated oil company. See also [http://www.sourcewatch.org/index.php?title=ExxonMobil Sourcewatch on ExxonMobil]<br />
<br />
He is also Vice President of the [[International Federation of Pharmaceutical Manufacturers and Associations]].<br />
<br />
He "earns more than $20m a year and was named 11th in the Fortune rankings of the world's most powerful business leaders." {{ref|guardianBoseley}}<br />
<br />
== External links ==<br />
* http://www.pfizer.com/pfizer/are/mn_about_message.jsp<br />
* http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html<br />
* http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=mco&script=2220&item_id=46518<br />
* http://www.sourcewatch.org/index.php?title=ExxonMobil<br />
{{note|guardian Boseley}} Sarah Boseley [http://education.guardian.co.uk/higher/research/story/0,,1310364,00.html 'We just had to act over Aids'], ''The Guardian'', September 23, 2004</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=29343International Federation of Pharmaceutical Manufacturers and Associations2006-04-25T16:35:55Z<p>Hmu05654: </p>
<hr />
<div>The '''International Federation of Pharmaceutical Manufacturers and Associations''' (IFPMA) describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The IFPMA is also a supporter of strong patent and intellectual property rights. [http://www.ifpma.org/Issues/issues.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" {{ref|haiwebWalt}}<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” {{ref|haiwebRichter}} <br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” {{ref|haiwebRichter}}<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” {{ref|haiwebWalt}}<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” {{ref|haiwebRundall}} <br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” {{ref|haiwebRichter}}<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” {{ref|haiwebRundall}} <br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” {{ref|haiwebRichter}}<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” {{ref|haiwebRichter}}<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” {{ref|haiwebRichter}}<br />
<br />
== Individuals ==<br />
<br />
=== IFPMA President ===<br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
=== IFPMA Vice Presidents ===<br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
=== Council members ===<br />
<br />
* [[Mr. Kazutaka Ichikawa]] of [[Japan Pharmaceutical Manufacturers Association]] - JPMA <br />
* [[Dr. Richard Barker]] of [[Association of the British Pharmaceutical Industry]] - ABPI <br />
* [[Mr. Billy Tauzin]] of [[Pharmaceutical Research and Manufacturers of America]] - PhRMA<br />
* [[Mr. Bernard Lemoine]]of [[Les Entreprises du Médicament]] - LEEM <br />
* [[Ms. Cornelia Yzer]] of [[Verband Forschender Arzneinmittelhersteller]] - VFA<br />
* [[Dr. Claudio Cavazza]] of [[Farmindustria]]<br />
* [[Mr. Thomas Cueni]] of [[INTERPHARMA]]<br />
* [[Ms. Sabrina Chan]] of [[Hong Kong Association of the Pharmaceutical Industry]]<br />
* [[Dr. João Gomes Esteves]]of [[APIFARMA]]<br />
* [[Mr. Jarmo Lehtonen]] of [[Pharma Industry Finland]] - PIF<br />
* [[Mr. Pavol Mazan]]of [[MAFS]]<br />
* [[Prof. Dr. Leo Neels]] of [[AGIM]]<br />
* [[Dr. Jorge Raimundo]]of [[INTERFARMA]]<br />
* [[Mr. Russell Williams]]of [[Canada's Research-Based Pharmaceutical Companies]]<br />
* [[Mrs Panida Panyangarm]] of [[Pharmaceutical Research and Manufacturers Association]] - PReMA <br />
* [[Mr. Ernesto Felicio]] of [[FIFARMA]] and [[CAEMe]]<br />
* [[Mr. Arthur Higgins]] of [[Bayer]] Healthcare AG<br />
* [[Mr. Miles White]] of [[Abbott Laboratories]]<br />
* [[Dr. Alessandro Banchi]] of [[Boehringer Ingelheim]]<br />
* [[Mr. Jean-François Dehecq]] of [[Sanofi Aventis]]<br />
* [[Dr. Jorge Gallardo]] of [[Almirall-Prodesfarma]]<br />
* [[Dr. Alberto Aleotti]] of [[Menarini SA]]<br />
* [[Dr. Franz B. Humer]] of [[F. Hoffmann-La Roche AG]]<br />
* [[Mr. Richard T. Clark]] of [[Merck]] & Co., Inc. <br />
* [[Mr. Elmar J. Schnee]] of [[Merck KGaA]]<br />
* [[Mr. Fred Hassan]] of [[Schering-Plough]] Corporation<br />
* [[Dr. Hatsuo Aoki]] of [[Fujisawa Pharmaceutical Co.]]<br />
* [[Dr. Jean-Pierre Garnier]] of [[GlaxoSmithKline]] <br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
=== Directors ===<br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Merck KGaA]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org<br />
* {{note|haiwebWalt}} Gill Walt [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2] "Using private money for public health: the growing trend towards partnership", November 3, 2000. <br />
* {{note|haiwebRichter}} Judith Richter [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3] "'Partnerships' between UN agencies and transnational companies: A critical perspective", November 3, 2000.<br />
* {{note|haiwebRundall}} Patti Rundall[http://www.haiweb.org/campaign/PPI/seminar200011.html#item6] "The Perils of Public-Private Partnerships: How do partnerships impact grassroots campaigns?", November 3, 2000.<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8341International Federation of Pharmaceutical Manufacturers and Associations2006-04-25T16:27:20Z<p>Hmu05654: </p>
<hr />
<div>The '''International Federation of Pharmaceutical Manufacturers and Associations''' (IFPMA) describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The IFPMA is also a supporter of strong patent and intellectual property rights. [http://www.ifpma.org/Issues/issues.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" {{ref|haiwebWalt}}<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” {{ref|haiwebRichter}} <br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” {{ref|haiwebRichter}}<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” {{ref|haiwebWalt}}<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” {{ref|haiwebRundall}} <br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” {{ref|haiwebRichter}}<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” {{ref|haiwebRundall}} <br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” {{ref|haiwebRichter}}<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” {{ref|haiwebRichter}}<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” {{ref|haiwebRichter}}<br />
<br />
== Individuals ==<br />
<br />
=== IFPMA President ===<br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
=== IFPMA Vice Presidents ===<br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
=== Council members ===<br />
<br />
* [[Mr. Kazutaka Ichikawa]] of [[Japan Pharmaceutical Manufacturers Association]] - JPMA <br />
* [[Dr. Richard Barker]] of [[Association of the British Pharmaceutical Industry]] - ABPI <br />
* [[Mr. Billy Tauzin]] of [[Pharmaceutical Research and Manufacturers of America]] - PhRMA<br />
* [[Mr. Bernard Lemoine]]of [[Les Entreprises du Médicament]] - LEEM <br />
* [[Ms. Cornelia Yzer]] of [[Verband Forschender Arzneinmittelhersteller]] - VFA<br />
* [[Dr. Claudio Cavazza]] of [[Farmindustria]]<br />
* [[Mr. Thomas Cueni]] of [[INTERPHARMA]]<br />
* [[Ms. Sabrina Chan]] of [[Hong Kong Association of the Pharmaceutical Industry]]<br />
* [[Dr. João Gomes Esteves]]of [[APIFARMA]]<br />
* [[Mr. Jarmo Lehtonen]] of [[Pharma Industry Finland]] - PIF<br />
* [[Mr. Pavol Mazan]]of [[MAFS]]<br />
* [[Prof. Dr. Leo Neels]] of [[AGIM]]<br />
* [[Dr. Jorge Raimundo]]of [[INTERFARMA]]<br />
* [[Mr. Russell Williams]]of [[Canada's Research-Based Pharmaceutical Companies]]<br />
* [[Mrs Panida Panyangarm]] of [[Pharmaceutical Research and Manufacturers Association]] - PReMA <br />
* [[Mr. Ernesto Felicio]] of [[FIFARMA]] and [[CAEMe]]<br />
* [[Mr. Arthur Higgins]] of [[Bayer]] Healthcare AG<br />
* [[Mr. Miles White]] of [[Abbott Laboratories]]<br />
* [[Dr. Alessandro Banchi]] of [[Boehringer Ingelheim]]<br />
* [[Mr. Jean-François Dehecq]] of [[Sanofi Aventis]]<br />
* [[Dr. Jorge Gallardo]] of [[Almirall-Prodesfarma]]<br />
* [[Dr. Alberto Aleotti]] of [[Menarini SA]]<br />
* [[Dr. Franz B. Humer]] of [[F. Hoffmann-La Roche AG]]<br />
* [[Mr. Richard T. Clark]] of [[Merck]] & Co., Inc. <br />
* [[Mr. Elmar J. Schnee]] of [[Merck KGaA]]<br />
* [[Mr. Fred Hassan]] of [[Schering-Plough]] Corporation<br />
* [[Dr. Hatsuo Aoki]] of [[Fujisawa Pharmaceutical Co.]]<br />
* [[Dr. Jean-Pierre Garnier]] of [[GlaxoSmithKline]] <br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
=== Directors ===<br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Merck KGaA]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org<br />
* {{note|haiwebWalt}} Gill Walt [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2] "Using private money for public health: the growing trend towards partnership", November 3, 2000. <br />
* {{note|haiwebRichter}} Judith Richter [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3] "'Partnerships' between UN agencies and transnational companies: A critical perspective", November 3, 2000.<br />
* {{note|haiwebRundall}} Patti Rundall[http://www.haiweb.org/campaign/PPI/seminar200011.html#item6] "The Perils of Public-Private Partnerships: How do partnerships impact grassroots campaigns?", November 3, 2000.<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=Haruo_Naito&diff=23982Haruo Naito2006-04-25T16:02:25Z<p>Hmu05654: </p>
<hr />
<div>Mr. Haruo Naito is President and CEO of [[Eisai]] Co., Ltd. of Japan.<br />
<br />
He played a key role in the establishment of the [[Health Care Science Institute]] that focuses on analysis and solutions for the complex problems and issues of international human health care.<br />
<br />
In April 1999, Mr. Naito was awarded an honorary CBE from the United Kingdom in recognition of his long-standing efforts in strengthening U.K. - Japan relations.<br />
[http://www.eisai.co.jp/enews/epdf20060222.pdf]<br />
<br />
== Further positions ==<br />
<br />
* on Northwestern University’s Kellogg Advisory Board <br />
* on Duke University’s Fuqua Board of Visitors<br />
* Vice President of the [[International Federation of Pharmaceutical Manufacturers and Associations]] (IFPMA)<br />
[http://www.eisai.co.jp/enews/epdf20060222.pdf]<br />
<br />
== External links ==<br />
* http://www.eisai.co.jp/enews/epdf20060222.pdf</div>Hmu05654https://powerbase.info/index.php?title=Haruo_Naito&diff=8336Haruo Naito2006-04-25T16:01:59Z<p>Hmu05654: </p>
<hr />
<div>Mr. Haruo Naito is President and CEO of [[Eisai]] Co., Ltd. of Japan.<br />
<br />
He played a key role in the establishment of the [[Health Care Science Institute]] that focuses on analysis and solutions for the complex problems and issues of international human health care.<br />
<br />
In April 1999, Mr. Naito was awarded an honorary CBE from the United Kingdom in recognition of his long-standing efforts in strengthening U.K. - Japan relations.<br />
[http://www.eisai.co.jp/enews/epdf20060222.pdf]<br />
<br />
== Further positions ==<br />
<br />
* on Northwestern University’s Kellogg Advisory Board <br />
* on Duke University’s Fuqua Board of Visitors<br />
* Vice President of the [[International Pharmaceutical Manufacturers Associations]] (IFPMA)<br />
[http://www.eisai.co.jp/enews/epdf20060222.pdf]<br />
<br />
== External links ==<br />
* http://www.eisai.co.jp/enews/epdf20060222.pdf</div>Hmu05654https://powerbase.info/index.php?title=Haruo_Naito&diff=8335Haruo Naito2006-04-25T16:01:41Z<p>Hmu05654: </p>
<hr />
<div>Mr. Haruo Naito is President and CEO of [[Eisai]] Co., Ltd. of Japan.<br />
<br />
He played a key role in the establishment of the [[Health Care Science Institute]] that focuses on analysis and solutions for the complex problems and issues of international human health care.<br />
<br />
In April 1999, Mr. Naito was awarded an honorary CBE from the United Kingdom in recognition of his long-standing efforts in strengthening U.K. - Japan relations.<br />
[http://www.eisai.co.jp/enews/epdf20060222.pdf]<br />
<br />
== Further positions ==<br />
<br />
* on Northwestern University’s Kellogg Advisory Board and <br />
* on Duke University’s Fuqua Board of Visitors<br />
* Vice President of the [[International Pharmaceutical Manufacturers Associations]] (IFPMA)<br />
[http://www.eisai.co.jp/enews/epdf20060222.pdf]<br />
<br />
== External links ==<br />
* http://www.eisai.co.jp/enews/epdf20060222.pdf</div>Hmu05654https://powerbase.info/index.php?title=Henry_A._McKinnell,_Jr.&diff=8989Henry A. McKinnell, Jr.2006-04-25T15:51:07Z<p>Hmu05654: </p>
<hr />
<div>"Dr. Henry A. McKinnell Jr. became chief executive officer of [[Pfizer]] in January 2001 and chairman of the board in April 2001 after holding a series of senior executive positions spanning more than 32 years with the company. During his time at Pfizer, McKinnell helped turn the company from a leader in the pharmaceutical industry into a "transforming force" with the acquisitions of Warner-Lambert in 2000 and Pharmacia in 2003 and the subsequent successful integration of both firms, forming a behemoth that earned $45 billion in 2003. Observers described McKinnell as polished, stately, and avuncular, yet also exacting, passionate, and sometimes impatient." [http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html]<br />
<br />
He is also chairman of the Governance and Compensation Committee and is a member of the Audit Committee of the Board of Directors. [http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=mco&script=2220&item_id=46518]<br />
<br />
Since 2002, he is a member of the Board of Directors [http://www.exxonmobil.com/Corporate/InvestorInfo/Corp_II_Board.asp] of [[ExxonMobil]], the world's largest integrated oil company. See also [http://www.sourcewatch.org/index.php?title=ExxonMobil Sourcewatch on ExxonMobil]<br />
<br />
He is also Vice President of the [[International Federation of Pharmaceutical Manufacturers and Associations]].<br />
<br />
== External links ==<br />
* http://www.pfizer.com/pfizer/are/mn_about_message.jsp<br />
* http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html<br />
* http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=mco&script=2220&item_id=46518<br />
* http://www.sourcewatch.org/index.php?title=ExxonMobil</div>Hmu05654https://powerbase.info/index.php?title=Henry_A._McKinnell,_Jr.&diff=8334Henry A. McKinnell, Jr.2006-04-25T15:35:37Z<p>Hmu05654: </p>
<hr />
<div>"Dr. Henry A. McKinnell Jr. became chief executive officer of Pfizer in January 2001 and chairman of the board in April 2001 after holding a series of senior executive positions spanning more than 32 years with the company. During his time at Pfizer, McKinnell helped turn the company from a leader in the pharmaceutical industry into a "transforming force" with the acquisitions of Warner-Lambert in 2000 and Pharmacia in 2003 and the subsequent successful integration of both firms, forming a behemoth that earned $45 billion in 2003. Observers described McKinnell as polished, stately, and avuncular, yet also exacting, passionate, and sometimes impatient." [http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html]<br />
<br />
He is also chairman of the Governance and Compensation Committee and is a member of the Audit Committee of the Board of Directors. [http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=mco&script=2220&item_id=46518]<br />
<br />
Since 2002, he is a member of the Board of Directors [http://www.exxonmobil.com/Corporate/InvestorInfo/Corp_II_Board.asp] of [[ExxonMobil]], the world's largest integrated oil company. See also [http://www.sourcewatch.org/index.php?title=ExxonMobil Sourcewatch on ExxonMobil]<br />
<br />
== External links ==<br />
* http://www.pfizer.com/pfizer/are/mn_about_message.jsp<br />
* http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html<br />
* http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=mco&script=2220&item_id=46518<br />
* http://www.sourcewatch.org/index.php?title=ExxonMobil</div>Hmu05654https://powerbase.info/index.php?title=Henry_A._McKinnell,_Jr.&diff=8332Henry A. McKinnell, Jr.2006-04-25T12:26:18Z<p>Hmu05654: </p>
<hr />
<div>"Dr. Henry A. McKinnell Jr. became chief executive officer of Pfizer in January 2001 and chairman of the board in April 2001 after holding a series of senior executive positions spanning more than 32 years with the company. During his time at Pfizer, McKinnell helped turn the company from a leader in the pharmaceutical industry into a "transforming force" with the acquisitions of Warner-Lambert in 2000 and Pharmacia in 2003 and the subsequent successful integration of both firms, forming a behemoth that earned $45 billion in 2003. Observers described McKinnell as polished, stately, and avuncular, yet also exacting, passionate, and sometimes impatient." [http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html]<br />
<br />
<br />
== External links ==<br />
* http://www.pfizer.com/pfizer/are/mn_about_message.jsp<br />
* http://www.referenceforbusiness.com/biography/M-R/McKinnell-Henry-A-Jr-1943.html</div>Hmu05654https://powerbase.info/index.php?title=Daniel_Vasella&diff=22889Daniel Vasella2006-04-25T12:12:48Z<p>Hmu05654: </p>
<hr />
<div>Dr. Daniel Vasella is a Medical Doctor and currently chairman and CEO of the pharmaceutical giant [[Novartis International AG]]. He has hold the position of chairman since 1999 and has been CEO of Novartis since 1996. That makes him the first Novartis CEO since the company was created through the merger of [[Sandoz]] and [[Ciba-Geigy]]. Before the merger he was CEO of [[Sandoz]] Pharma Ltd. [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
He suffered a breakdown in his thirties and consulted psychotherapy after which he gave up his profession as MD and head of a hospital and became a travelling salesman for [[Sandoz]] in New Jersey. He rose in the company and finally played an important role in the merger.<br />
His considerably younger wife is the niece of a former [[Sandoz]] chairman which led to accusations of nepotism. [http://news.bbc.co.uk/1/hi/business/4167921.stm]<br />
<br />
"Last year, he was named "the most influential European business leader of the last 25 years" in a poll of Financial Times readers. [...] Dr Vasella's success has brought him considerable personal wealth. In 2003, his basic salary of $ 2.2m was part of a $14.4m pay package which made him one of the best paid bosses in Europe." [http://news.bbc.co.uk/1/hi/business/4167921.stm]<br />
<br />
== Dr. Vasella on corporate responsibility and "drugs for the poor " ==<br />
<br />
From the BBC news website: <br />
" "Profits provide freedom," he [i.e. Vasella] points out. When deciding on where to channel its R&D budgets, Dr Vasella explains, Novartis goes "medical need, but also economic need". <br />
<br />
"I find this legitimate. It makes sense, ethically and financially." <br />
<br />
This free market formula may work in a wealthy society, but it falls apart when it comes to the search for malaria drugs, anti-retroviral drugs or other medicines for developing world diseases, Dr Vasella acknowledges. <br />
<br />
But that, he insists, is not merely the fault of pharmaceutical companies. Rich Western nations and corrupt governments in poor countries should also be blamed for any failure to help. <br />
<br />
"I think it's a common responsibility," he says, insisting both Novartis and many of its competitors are pulling their weight. <br />
<br />
For instance; Novartis and the Novartis Foundation for Sustainable Development provide free treatment for all leprosy patients in the world. Malaria drugs are provided at cost via the World Health Organisation. In the US the company provides social investment to improve healthcare for some of the 36 million people without health insurance. <br />
<br />
"Is it perfect? It is not perfect, but we also have to learn to move ahead with things that are not perfect. I think it is better to do something than nothing," Dr Vasella says. <br />
<br />
"I think shareholders can protest if they don't like it, but you know, they don't." " [http://news.bbc.co.uk/1/hi/business/4167921.stm]<br />
<br />
== Memberships ==<br />
<br />
Dr. Vasella holds a number of positions: <br />
* member of the Board of Directors of [[PepsiCo Inc.]] [http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* former member of the Board of Directors of [[Credit Suisse Group]] (stepped down in 2003 after 6 years of membership)[http://www.credit-suisse.com/upload/news-live/27364_1001.pdf]<br />
* member of the Supervisory Board of [[Siemens AG]] until 2003 [http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879]<br />
* member of the Chairman's Council of [[DaimlerChrysler]] [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
* chairman of the International Business Leaders Advisory Council for the Mayor of Shanghai [http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* member of the International Board of Governors of the [[Peres Center for Peace]] in Israel<br />
* member of the Board of Dean's Advisors at the Harvard Business School<br />
* president of the [[International Federation of Pharmaceutical Manufacturers and Associations]] [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
== External links ==<br />
* http://www.ifpma.org/About_Us/about_vasella.aspx<br />
* http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
*http://news.bbc.co.uk/1/hi/business/4167921.stm<br />
* http://www.credit-suisse.com/upload/news-live/27364_1001.pdf<br />
* http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879</div>Hmu05654https://powerbase.info/index.php?title=Daniel_Vasella&diff=8267Daniel Vasella2006-04-25T11:37:19Z<p>Hmu05654: </p>
<hr />
<div>Dr. Daniel Vasella is a Medical Doctor and currently chairman and CEO of the pharmaceutical giant [[Novartis International AG]]. He has hold the position of chairman since 1999 and has been CEO of Novartis since 1996. That makes him the first Novartis CEO since the company was created through the merger of [[Sandoz]] and [[Ciba-Geigy]]. Before the merger he was CEO of [[Sandoz]] Pharma Ltd. [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
He suffered a breakdown in his thirties and consulted psychotherapy after which he gave up his profession as MD and head of a hospital and became a travelling salesman for [[Sandoz]] in New Jersey. He rose in the company and finally played an important role in the merger.<br />
His considerably younger wife is the niece of a former [[Sandoz]] chairman which led to accusations of nepotism. [http://news.bbc.co.uk/1/hi/business/4167921.stm]<br />
<br />
"Last year, he was named "the most influential European business leader of the last 25 years" in a poll of Financial Times readers. [...] Dr Vasella's success has brought him considerable personal wealth. In 2003, his basic salary of $ 2.2m was part of a $14.4m pay package which made him one of the best paid bosses in Europe." [http://news.bbc.co.uk/1/hi/business/4167921.stm]<br />
<br />
== Memberships ==<br />
<br />
Dr. Vasella holds a number of positions: <br />
* member of the Board of Directors of [[PepsiCo Inc.]] [http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* former member of the Board of Directors of [[Credit Suisse Group]] (stepped down in 2003 after 6 years of membership)[http://www.credit-suisse.com/upload/news-live/27364_1001.pdf]<br />
* member of the Supervisory Board of [[Siemens AG]] until 2003 [http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879]<br />
* member of the Chairman's Council of [[DaimlerChrysler]] [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
* chairman of the International Business Leaders Advisory Council for the Mayor of Shanghai [http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* member of the International Board of Governors of the [[Peres Center for Peace]] in Israel<br />
* member of the Board of Dean's Advisors at the Harvard Business School<br />
* president of the [[International Federation of Pharmaceutical Manufacturers and Associations]] [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
== External links ==<br />
* http://www.ifpma.org/About_Us/about_vasella.aspx<br />
* http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
*http://news.bbc.co.uk/1/hi/business/4167921.stm<br />
* http://www.credit-suisse.com/upload/news-live/27364_1001.pdf<br />
* http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879</div>Hmu05654https://powerbase.info/index.php?title=Daniel_Vasella&diff=8245Daniel Vasella2006-04-25T11:35:56Z<p>Hmu05654: </p>
<hr />
<div>Dr. Daniel Vasella is a Medical Doctor and currently chairman and CEO of the pharmaceutical giant [[Novartis]]. He has hold the position of chairman since 1999 and has been CEO of Novartis since 1996. That makes him the first Novartis CEO since the company was created through the merger of [[Sandoz]] and [[Ciba-Geigy]]. Before the merger he was CEO of [[Sandoz]] Pharma Ltd. [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
He suffered a breakdown in his thirties and consulted psychotherapy after which he gave up his profession as MD and head of a hospital and became a travelling salesman for [[Sandoz]] in New Jersey. He rose in the company and finally played an important role in the merger.<br />
His considerably younger wife is the niece of a former [[Sandoz]] chairman which led to accusations of nepotism. [http://news.bbc.co.uk/1/hi/business/4167921.stm]<br />
<br />
"Last year, he was named "the most influential European business leader of the last 25 years" in a poll of Financial Times readers. [...] Dr Vasella's success has brought him considerable personal wealth. In 2003, his basic salary of $ 2.2m was part of a $14.4m pay package which made him one of the best paid bosses in Europe." [http://news.bbc.co.uk/1/hi/business/4167921.stm]<br />
<br />
== Memberships ==<br />
<br />
Dr. Vasella holds a number of positions: <br />
* member of the Board of Directors of [[PepsiCo Inc.]] [http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* former member of the Board of Directors of [[Credit Suisse Group]] (stepped down in 2003 after 6 years of membership)[http://www.credit-suisse.com/upload/news-live/27364_1001.pdf]<br />
* member of the Supervisory Board of [[Siemens AG]] until 2003 [http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879]<br />
* member of the Chairman's Council of [[DaimlerChrysler]] [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
* chairman of the International Business Leaders Advisory Council for the Mayor of Shanghai [http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* member of the International Board of Governors of the [[Peres Center for Peace]] in Israel<br />
* member of the Board of Dean's Advisors at the Harvard Business School<br />
* president of the [[International Federation of Pharmaceutical Manufacturers and Associations]] [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
== External links ==<br />
* http://www.ifpma.org/About_Us/about_vasella.aspx<br />
* http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
*http://news.bbc.co.uk/1/hi/business/4167921.stm<br />
* http://www.credit-suisse.com/upload/news-live/27364_1001.pdf<br />
* http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879</div>Hmu05654https://powerbase.info/index.php?title=Daniel_Vasella&diff=8244Daniel Vasella2006-04-25T11:26:05Z<p>Hmu05654: </p>
<hr />
<div>Dr. Daniel Vasella is a Medical Doctor and currently chairman and CEO of the pharmaceutical giant [[Novartis]]. He has hold the position of chairman since 1999 and has been CEO of Novartis since 1996. That makes him the first Novartis CEO since the company was created through the merger of [[Sandoz]] and [[Ciba-Geigy]]. Before the merger he was CEO of [[Sandoz]] Pharma Ltd. [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
== Memberships ==<br />
<br />
Dr. Vasella holds a number of positions: <br />
* member of the Board of Directors of [[PepsiCo Inc.]] [http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* former member of the Board of Directors of [[Credit Suisse Group]] (stepped down in 2003 after 6 years of membership)[http://www.credit-suisse.com/upload/news-live/27364_1001.pdf]<br />
* member of the Supervisory Board of [[Siemens AG]] until 2003 [http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879]<br />
* member of the Chairman's Council of [[DaimlerChrysler]] [http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
* chairman of the International Business Leaders Advisory Council for the Mayor of Shanghai <br />
[http://www.ifpma.org/About_Us/about_vasella.aspx]<br />
* member of the International Board of Governors of the [[Peres Center for Peace]] in Israel<br />
* member of the Board of Dean's Advisors at the Harvard Business School<br />
* president of the [[International Federation of Pharmaceutical Manufacturers and Associations]]<br />
[http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
<br />
== External links ==<br />
* http://www.ifpma.org/About_Us/about_vasella.aspx<br />
* http://www.novartis.com/downloads_new/management_CV/CV_Daniel_Vasella_E.pdf]<br />
* http://www.credit-suisse.com/upload/news-live/27364_1001.pdf<br />
* http://www.logistics-assembly.siemens.com/bausteine.net/file/showfile.aspx?downdaid=5879</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8338International Federation of Pharmaceutical Manufacturers and Associations2006-04-25T10:24:19Z<p>Hmu05654: </p>
<hr />
<div>The '''International Federation of Pharmaceutical Manufacturers and Associations''' (IFPMA) describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The IFPMA is also a supporter of strong patent and intellectual property rights. [http://www.ifpma.org/Issues/issues.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" {{ref|haiwebWalt}}<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” {{ref|haiwebRichter}} <br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” {{ref|haiwebRichter}}<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” {{ref|haiwebWalt}}<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” {{ref|haiwebRundall}} <br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” {{ref|haiwebRichter}}<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” {{ref|haiwebRundall}} <br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” {{ref|haiwebRichter}}<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” {{ref|haiwebRichter}}<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” {{ref|haiwebRichter}}<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Merck KGaA]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org<br />
* {{note|haiwebWalt}} Gill Walt [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2] "Using private money for public health: the growing trend towards partnership", November 3, 2000. <br />
* {{note|haiwebRichter}} Judith Richter [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3] "'Partnerships' between UN agencies and transnational companies: A critical perspective", November 3, 2000.<br />
* {{note|haiwebRundall}} Patti Rundall[http://www.haiweb.org/campaign/PPI/seminar200011.html#item6] "The Perils of Public-Private Partnerships: How do partnerships impact grassroots campaigns?", November 3, 2000.<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8161International Federation of Pharmaceutical Manufacturers and Associations2006-04-25T09:48:25Z<p>Hmu05654: </p>
<hr />
<div>The '''International Federation of Pharmaceutical Manufacturers and Associations''' (IFPMA) describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" {{ref|haiwebWalt}}<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” {{ref|haiwebRichter}} <br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” {{ref|haiwebRichter}}<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” {{ref|haiwebWalt}}<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” {{ref|haiwebRundall}} <br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” {{ref|haiwebRichter}}<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” {{ref|haiwebRundall}} <br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” {{ref|haiwebRichter}}<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” {{ref|haiwebRichter}}<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” {{ref|haiwebRichter}}<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Merck KGaA]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org<br />
* {{note|haiwebWalt}} Gill Walt [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2] "Using private money for public health: the growing trend towards partnership", November 3, 2000. <br />
* {{note|haiwebRichter}} Judith Richter [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3] "'Partnerships' between UN agencies and transnational companies: A critical perspective", November 3, 2000.<br />
* {{note|haiwebRundall}} Patti Rundall[http://www.haiweb.org/campaign/PPI/seminar200011.html#item6] "The Perils of Public-Private Partnerships: How do partnerships impact grassroots campaigns?", November 3, 2000.<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8128International Federation of Pharmaceutical Manufacturers and Associations2006-04-25T09:43:59Z<p>Hmu05654: </p>
<hr />
<div>The '''International Federation of Pharmaceutical Manufacturers and Associations''' (IFPMA) describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" {{ref|haiwebWalt}}<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” {{ref|haiwebRichter}} <br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” {{ref|haiwebRichter}}<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” {{ref|haiwebWalt}}<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” {{ref|haiwebRichter}}<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” {{ref|haiwebRichter}}<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” {{ref|haiwebRichter}}<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” {{ref|haiwebRichter}}<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Merck KGaA]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org<br />
* {{note|haiwebWalt}} Gill Walt [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2] "Using private money for public health: the growing trend towards partnership", November 3, 2000. <br />
* {{note|haiwebRichter}} Judith Richter [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3] "'Partnerships' between UN agencies and transnational companies: A critical perspective", November 3, 2000.<br />
* {{note|haiwebRundall}} Patti Rundall[http://www.haiweb.org/campaign/PPI/seminar200011.html#item6] "The Perils of Public-Private Partnerships: How do partnerships impact grassroots campaigns?", November 3, 2000.<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8127International Federation of Pharmaceutical Manufacturers and Associations2006-04-25T09:29:52Z<p>Hmu05654: </p>
<hr />
<div>The '''International Federation of Pharmaceutical Manufacturers and Associations''' (IFPMA) describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" {{ref|haiwebWalt}}<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Merck KGaA]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org<br />
* {{note|haiwebWalt}} Gill Walt [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2] "Using private money for public health: the growing trend towards partnership", November 3, 2000. <br />
* http://www.haiweb.org/campaign/PPI/seminar200011.html#item3<br />
* http://www.haiweb.org/campaign/PPI/seminar200011.html#item6<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=IFPMA&diff=8104IFPMA2006-04-25T08:03:43Z<p>Hmu05654: </p>
<hr />
<div></div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=9158Merck and Co. Inc.2006-04-24T20:35:48Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== The company ==<br />
<br />
Merck & Co., Inc. should not be confused with [[Merck KGaA]]. While [[Merck KGaA]] is allegedly the World's oldest pharmaceutical and chemical company and based in Germany, the U.S. company Merck & Co. became independent after the First World War. [http://pb.merck.de/servlet/PB/menu/1014710/index.html] <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
From the Merck website:<br />
"At Merck, our business is discovering, developing and delivering novel medicines and vaccines that can make a difference in people's lives. But our mission also entails something more. As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for patients. And we are committed to our employees, to the environment in which we live and to the communities we serve worldwide." [http://www.merck.com/cr/]<br />
<br />
This statement has to be seen in contrast with Merck's Vioxx scandal and their range of products, especially the absence of any Malaria treatment.<br />
"Malaria kills an estimated 2.5 million people a year, the majority of these African children aged below five years old. While western pharmaceutical companies have invested approximately £ 11bn over the past decade in "lifestyle drugs" for impotence, weight loss, baldness, smoking and ageing, the product development budget for the Tropical Disease Research (TDR) programme, a joint<br />
effort from the [[World Health Organisation]] (WHO), [[World Bank]], and [[United Nations Development Programme]] (UNDP), averages £ 6m per year. [..] It would be impossible for the drugs companies to make a profit in African and Asian countries where the average wage can be as little as £ 1 per day and, in Africa, economic growth is slowing by 1.3% per year as a direct result of malaria alone." (''The Herald'' (Glasgow), August 20, 2004)<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are partly not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
From the Guardian, March 16, 2006: <br />
"Thousands of patients are now suing manufacturers Merck after the company was forced to withdraw the painkiller, widely used by arthritis sufferers, in 2004. Data from its trials had emerged showing that it increased the risks of heart attack. David Graham of the Food and Drug Administration, the US drug regulator, said it could have caused up to 140,000 cases of heart disease in the US since it was licensed in 1999." <br />
<br />
Merck keeps claiming they '''voluntarily''' withdrew Vioxx from the market. [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp]<br />
<br />
"Insider emails published by the Wall Street Journal reveal that Merck, the maker of Vioxx, was fully aware of the health risks of its COX-2 inhibitor anti-inflammatory drug as early as March, 2000. As is apparent from the published emails, there was a concerted effort to bury the negative evidence and even distort the drug trials by excluding heart patients from the Vioxx studies so that, "...the rate of cardiovascular problems for Vioxx patients would not be evident." " [http://www.newstarget.com/002155.html]<br />
<br />
== Management committee ==<br />
<br />
* [[Richard T. Clark]], CEO and president<br />
* [[David W. Anstice]], president, Human Health-Asia Pacific<br />
* [[Willie A. Deese]], president, Merck Manufacturing Division <br />
* [[Kenneth C. Frazier]], senior vice president and general counsel<br />
* [[Peter S. Kim]], Ph.D., president, Merck Research Laboratories (MRL)<br />
* [[Judy C. Lewent]], executive vice president and chief financial officer <br />
* [[Adel A.F. Mahmoud]], M.D., Ph.D., chief medical advisor, Vaccines and Infectious Diseases<br />
* [[Margaret G. McGlynn]], president, Merck Vaccine Division (MVD)<br />
* [[J. Chris Scalet]], senior vice president, Global Process and Services, and Chief Information Officer<br />
* [[Bradley T. Sheares]], Ph.D., president, U.S. Human Health<br />
* [[Per Wold-Olsen]], president, Human Health - Intercontinental<br />
[http://www.merck.com/about/management_committee/home.html]<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com<br />
* http://www.msnbc.msn.com/id/6192603/<br />
*http://pb.merck.de/servlet/PB/menu/1014710/index.html<br />
* Beth Pearson, "Malaria: why make a killing?;It kills 2.5 million people every year, yet no one was interested in finding a cure. There just wasn't enough profit in it. Now scientists in Dundee are leading a pharmaceutical revolution", ''The Herald'' (Glasgow), August 20, 2004.<br />
* http://www.rotateq.com/<br />
* http://www.crixivan.com/<br />
* http://www.emend.com/<br />
* http://www.fosamax.com/<br />
* http://www.maxalt.com/<br />
* http://www.propecia.com/<br />
* http://www.proscar.com/<br />
* http://www.singulair.com/<br />
* http://www.vioxx.com/<br />
* http://www.zocor.com/<br />
* Sarah Boseley, "G2: From test-tube to medicine cabinet: How a new drug makes it on to the market", ''The Guardian'', March 16, 2006<br />
* http://www.newstarget.com/002155.html<br />
<br />
<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8084Merck and Co. Inc.2006-04-24T20:26:23Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== The company ==<br />
<br />
Merck & Co., Inc. should not be confused with [[Merck KGaA]]. While [[Merck KGaA]] is allegedly the World's oldest pharmaceutical and chemical company and based in Germany, the U.S. company Merck & Co. became independent after the First World War. [http://pb.merck.de/servlet/PB/menu/1014710/index.html] <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
From the Merck website:<br />
"At Merck, our business is discovering, developing and delivering novel medicines and vaccines that can make a difference in people's lives. But our mission also entails something more. As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for patients. And we are committed to our employees, to the environment in which we live and to the communities we serve worldwide." [http://www.merck.com/cr/]<br />
<br />
This statement has to be seen in contrast with Merck's Vioxx scandal and their range of products, especially the absence of any Malaria treatment.<br />
"Malaria kills an estimated 2.5 million people a year, the majority of these African children aged below five years old. While western pharmaceutical companies have invested approximately £ 11bn over the past decade in "lifestyle drugs" for impotence, weight loss, baldness, smoking and ageing, the product development budget for the Tropical Disease Research (TDR) programme, a joint<br />
effort from the [[World Health Organisation]] (WHO), [[World Bank]], and [[United Nations Development Programme]] (UNDP), averages £ 6m per year. [..] It would be impossible for the drugs companies to make a profit in African and Asian countries where the average wage can be as little as £ 1 per day and, in Africa, economic growth is slowing by 1.3% per year as a direct result of malaria alone." (''The Herald'' (Glasgow), August 20, 2004)<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are partly not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
From the Guardian, March 16, 2006: <br />
"Thousands of patients are now suing manufacturers Merck after the company was forced to withdraw the painkiller, widely used by arthritis sufferers, in 2004. Data from its trials had emerged showing that it increased the risks of heart attack. David Graham of the Food and Drug Administration, the US drug regulator, said it could have caused up to 140,000 cases of heart disease in the US since it was licensed in 1999." <br />
<br />
Merck keeps claiming they '''voluntarily''' withdrew Vioxx from the market. [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp]<br />
<br />
"Insider emails published by the Wall Street Journal reveal that Merck, the maker of Vioxx, was fully aware of the health risks of its COX-2 inhibitor anti-inflammatory drug as early as March, 2000. As is apparent from the published emails, there was a concerted effort to bury the negative evidence and even distort the drug trials by excluding heart patients from the Vioxx studies so that, "...the rate of cardiovascular problems for Vioxx patients would not be evident." " [http://www.newstarget.com/002155.html]<br />
<br />
== Management committee ==<br />
<br />
* [[Richard T. Clark]], CEO and president<br />
* [[David W. Anstice]], president, Human Health-Asia Pacific<br />
* [[Willie A. Deese]], president, Merck Manufacturing Division <br />
* [[Kenneth C. Frazier]], senior vice president and general counsel<br />
* [[Peter S. Kim]], Ph.D., president, Merck Research Laboratories (MRL)<br />
* [[Judy C. Lewent]], executive vice president and chief financial officer <br />
* [[Adel A.F. Mahmoud]], M.D., Ph.D., chief medical advisor, Vaccines and Infectious Diseases<br />
* [[Margaret G. McGlynn]], president, Merck Vaccine Division (MVD)<br />
* [[J. Chris Scalet]], senior vice president, Global Process and Services, and Chief Information Officer<br />
* [[Bradley T. Sheares]], Ph.D., president, U.S. Human Health<br />
* [[Per Wold-Olsen]], president, Human Health - Intercontinental<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com<br />
* Beth Pearson, "Malaria: why make a killing?;It kills 2.5 million people every year, yet no one was interested in finding a cure. There just wasn't enough profit in it. Now scientists in Dundee are leading a pharmaceutical revolution", ''The Herald'' (Glasgow), August 20, 2004.<br />
* Sarah Boseley, “G2: From test-tube to medicine cabinet: How a new drug makes it on to the market”, ‘’The Guardian’’, March 16, 2006<br />
<br />
<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8082Merck and Co. Inc.2006-04-24T18:32:01Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== The company ==<br />
<br />
Merck & Co., Inc. should not be confused with [[Merck KGaA]]. While [[Merck KGaA]] is allegedly the World's oldest pharmaceutical and chemical company and based in Germany, the U.S. company Merck & Co. became independent after the First World War. [http://pb.merck.de/servlet/PB/menu/1014710/index.html] <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
From the Merck website:<br />
"At Merck, our business is discovering, developing and delivering novel medicines and vaccines that can make a difference in people's lives. But our mission also entails something more. As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for patients. And we are committed to our employees, to the environment in which we live and to the communities we serve worldwide." [http://www.merck.com/cr/]<br />
<br />
This statement has to be seen in contrast with Merck's Vioxx scandal and their range of products, especially the absence of any Malaria treatment.<br />
"Malaria kills an estimated 2.5 million people a year, the majority of these African children aged below five years old. While western pharmaceutical companies have invested approximately £ 11bn over the past decade in "lifestyle drugs" for impotence, weight loss, baldness, smoking and ageing, the product development budget for the Tropical Disease Research (TDR) programme, a joint<br />
effort from the [[World Health Organisation]] (WHO), [[World Bank]], and [[United Nations Development Programme]] (UNDP), averages £ 6m per year. [..] It would be impossible for the drugs companies to make a profit in African and Asian countries where the average wage can be as little as £ 1 per day and, in Africa, economic growth is slowing by 1.3% per year as a direct result of malaria alone." (''The Herald'' (Glasgow), August 20, 2004)<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are partly not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com<br />
* Beth Pearson, "Malaria: why make a killing?;It kills 2.5 million people every year, yet no one was interested in finding a cure. There just wasn't enough profit in it. Now scientists in Dundee are leading a pharmaceutical revolution", ''The Herald'' (Glasgow), August 20, 2004.<br />
<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8063Merck and Co. Inc.2006-04-24T18:24:57Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== History and importance ==<br />
<br />
Merck & Co., Inc. should not be confused with [[Merck KGaA]]. While [[Merck KGaA]] is allegedly the World's oldest pharmaceutical and chemical company and based in Germany, the U.S. company Merck & Co. became independent after the First World War. [http://pb.merck.de/servlet/PB/menu/1014710/index.html] <br />
<br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
From the Merck website:<br />
"At Merck, our business is discovering, developing and delivering novel medicines and vaccines that can make a difference in people's lives. But our mission also entails something more. As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for patients. And we are committed to our employees, to the environment in which we live and to the communities we serve worldwide." [http://www.merck.com/cr/]<br />
<br />
This statement has to be seen in contrast with Merck's Vioxx scandal and their range of products, especially the absence of any Malaria treatment.<br />
"Malaria kills an estimated 2.5 million people a year, the majority of these African children aged below five years old. While western pharmaceutical companies have invested approximately £ 11bn over the past decade in "lifestyle drugs" for impotence, weight loss, baldness, smoking and ageing, the product development budget for the Tropical Disease Research (TDR) programme, a joint<br />
effort from the [[World Health Organisation]] (WHO), [[World Bank]], and [[United Nations Development Programme]] (UNDP), averages £ 6m per year. [..] It would be impossible for the drugs companies to make a profit in African and Asian countries where the average wage can be as little as £ 1 per day and, in Africa, economic growth is slowing by 1.3% per year as a direct result of malaria alone." (''The Herald'' (Glasgow), August 20, 2004)<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are partly not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com<br />
* Beth Pearson, "Malaria: why make a killing?;It kills 2.5 million people every year, yet no one was interested in finding a cure. There just wasn't enough profit in it. Now scientists in Dundee are leading a pharmaceutical revolution", ''The Herald'' (Glasgow), August 20, 2004.<br />
<br />
<br />
[[Category:Pharmaceutical Industry]]</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8056Merck and Co. Inc.2006-04-24T18:16:03Z<p>Hmu05654: WH</p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== History and importance ==<br />
<br />
Merck & Co., Inc. should not be confused with [[Merck KGaA]]. <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
From the Merck website:<br />
"At Merck, our business is discovering, developing and delivering novel medicines and vaccines that can make a difference in people's lives. But our mission also entails something more. As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for patients. And we are committed to our employees, to the environment in which we live and to the communities we serve worldwide." [http://www.merck.com/cr/]<br />
<br />
This statement has to be seen in contrast with Merck's Vioxx scandal and their range of products, especially the absence of any Malaria treatment.<br />
"Malaria kills an estimated 2.5 million people a year, the majority of these African children aged below five years old. While western pharmaceutical companies have invested approximately £ 11bn over the past decade in "lifestyle drugs" for impotence, weight loss, baldness, smoking and ageing, the product development budget for the Tropical Disease Research (TDR) programme, a joint<br />
effort from the [[World Health Organisation]] (WHO), [[World Bank]], and [[United Nations Development Programme]] (UNDP), averages £ 6m per year. [..] It would be impossible for the drugs companies to make a profit in African and Asian countries where the average wage can be as little as £ 1 per day and, in Africa, economic growth is slowing by 1.3% per year as a direct result of malaria alone." (''The Herald'' (Glasgow), August 20, 2004)<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are partly not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com<br />
* Beth Pearson, "Malaria: why make a killing?;It kills 2.5 million people every year, yet no one was interested in finding a cure. There just wasn't enough profit in it. Now scientists in Dundee are leading a pharmaceutical revolution", ''The Herald'' (Glasgow), August 20, 2004.</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8047Merck and Co. Inc.2006-04-24T18:08:45Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
From the Merck website:<br />
"At Merck, our business is discovering, developing and delivering novel medicines and vaccines that can make a difference in people's lives. But our mission also entails something more. As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for patients. And we are committed to our employees, to the environment in which we live and to the communities we serve worldwide." [http://www.merck.com/cr/]<br />
<br />
This statement has to be seen in contrast with Merck's Vioxx scandal and their range of products, especially the absence of any Malaria treatment.<br />
"Malaria kills an estimated 2.5 million people a year, the majority of these African children aged below five years old. While western pharmaceutical companies have invested approximately £ 11bn over the past decade in "lifestyle drugs" for impotence, weight loss, baldness, smoking and ageing, the product development budget for the Tropical Disease Research (TDR) programme, a joint<br />
effort from the [[World Health Organisation]] (WHO), [[World Bank]], and [[United Nations Development Programme]] (UNDP), averages £ 6m per year. [..] It would be impossible for the drugs companies to make a profit in African and Asian countries where the average wage can be as little as £ 1 per day and, in Africa, economic growth is slowing by 1.3% per year as a direct result of malaria alone." (''The Herald'' (Glasgow), August 20, 2004)<br />
<br />
<br />
== Market share and importance == <br />
<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are partly not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com<br />
* Beth Pearson, "Malaria: why make a killing?;It kills 2.5 million people every year, yet no one was interested in finding a cure. There just wasn't enough profit in it. Now scientists in Dundee are leading a pharmaceutical revolution", ''The Herald'' (Glasgow), August 20, 2004.</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8046Merck and Co. Inc.2006-04-24T18:08:10Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
From the Merck website:<br />
"At Merck, our business is discovering, developing and delivering novel medicines and vaccines that can make a difference in people's lives. But our mission also entails something more. As a Company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for patients. And we are committed to our employees, to the environment in which we live and to the communities we serve worldwide." [http://www.merck.com/cr/]<br />
<br />
This statement has to be seen in contrast with Merck's Vioxx scandal and their range of products, especially the absence of any Malaria treatment.<br />
"Malaria kills an estimated 2.5 million people a year, the majority of these African children aged below five years old. While western pharmaceutical companies have invested approximately £ 11bn over the past decade in "lifestyle drugs" for impotence, weight loss, baldness, smoking and ageing, the product development budget for the Tropical Disease Research (TDR) programme, a joint<br />
effort from the [[World Health Organisation]] (WHO), [[World Bank]], and [[United Nations Development Programme]] (UNDP), averages £ 6m per year. [..] It would be impossible for the drugs companies to make a profit in African and Asian countries where the average wage can be as little as £ 1 per day and, in Africa, economic growth is slowing by 1.3% per year as a direct result of malaria alone." (''The Herald'' (Glasgow), August 20, 2004)<br />
<br />
<br />
== Market share and importance == <br />
<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are partly not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com<br />
Beth Pearson, "Malaria: why make a killing?;It kills 2.5 million people every year, yet no one was interested in finding a cure. There just wasn't enough profit in it. Now scientists in Dundee are leading a pharmaceutical revolution", ''The Herald'' (Glasgow), August 20, 2004.</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8045Merck and Co. Inc.2006-04-24T17:49:01Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
<br />
== Market share and importance == <br />
<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are not approved yet.<br />
<br />
Patients get information on: <br />
* '''Rotateq''', a rotavirus vaccine for children [http://www.rotateq.com/]<br />
* '''Crixivan''', an antiretroviral agent for HIV patients, recommended to be taken in combination with other antiretroviral agents [http://www.crixivan.com/indinavir_sulfate/crixivan/consumer/index.jsp]<br />
* '''Emend''', a medication to suppress nausea and vomiting as side effects of chemotherapy [http://www.emend.com/aprepitant/emend/consumer/index.jsp]<br />
* '''Fosamax''', an Osteoporosis medication [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Fosamax Plus D''', with added vitamin D [http://www.fosamax.com/alendronate_sodium/fosamax/consumer/index.jsp]<br />
* '''Maxalt''', a painkiller for migraine patients [http://www.maxalt.com/rizatriptan_benzoate/maxalt/consumer/index.jsp]<br />
* '''Propecia''', treatment for male hair loss [http://www.propecia.com/finasteride/propecia/consumer/index.jsp?mtc=40NOSURVEY]<br />
* '''Proscar''', a medication for prostate treatment [http://www.proscar.com/proscar_finasteride/proscar/consumer/index.jsp]<br />
* '''Singulair''', an asthma and allergy treatment [http://www.singulair.com/montelukast_sodium/singulair/consumer/index2.jsp]<br />
* '''Vioxx''', a painkiller for arthritis patients. The link [http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp] provided by Merck only shows Merck's hideous attempt to justify the Vioxx scandal (see below)<br />
* '''Zocor''', a cholesterol medication [http://www.zocor.com/simvastatin/zocor/consumer/index.jsp]<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8040Merck and Co. Inc.2006-04-24T17:14:37Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== Corporate social responsibility at Merck == <br />
<br />
<br />
== Market share and importance == <br />
<br />
<br />
== Products == <br />
<br />
Merck provides different lists of products for patients and healthcare professionals. That for professionals includes medicines and a vaccine that are not approved yet.<br />
<br />
Patients get information on: <br />
* '''Crixivan''', <br />
* '''Emend'''<br />
* '''Fosamax'''<br />
* '''Fosamax Plus D'''<br />
* '''Maxalt'''<br />
* '''Propecia'''<br />
* '''Proscar'''<br />
* '''Singulair'''<br />
* '''Vioxx'''<br />
* '''Zocor'''<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==<br />
<br />
* http://www.merck.com</div>Hmu05654https://powerbase.info/index.php?title=Merck_and_Co._Inc.&diff=8029Merck and Co. Inc.2006-04-24T16:51:22Z<p>Hmu05654: </p>
<hr />
<div>Merck & Co., Inc. describes itself as "a global research-driven pharmaceutical company dedicated to putting patients first." [http://www.merck.com/about/] "Putting patients first" has so far "led to more than 27,000 heart attacks and sudden cardiac deaths" [http://www.msnbc.msn.com/id/6192603/] through their arthritis treatment Vioxx between its approval in 1999 and its withdrawal from the market in 2004. <br />
<br />
== History == <br />
<br />
<br />
== Market share and importance == <br />
<br />
<br />
== Products == <br />
<br />
<br />
== The Vioxx scandal == <br />
<br />
<br />
== Management committee ==<br />
<br />
<br />
== External links ==</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8072International Federation of Pharmaceutical Manufacturers and Associations2006-04-24T16:32:57Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Merck KGaA]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8008International Federation of Pharmaceutical Manufacturers and Associations2006-04-24T16:11:17Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck]]<br />
* [[Menarini S.A.]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=8001International Federation of Pharmaceutical Manufacturers and Associations2006-04-24T15:56:37Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== The term itself ===<br />
<br />
In most cases ‘partnership’ is simply a euphemism for 'strategic sponsorship' or lobby activities. What, then, is sponsorship? “It is not a philanthropic gift. It is a commercial deal. Sponsorship is a payment by a business firm for the purpose of promoting its name, products or services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“In fact, many of the interactions, which are currently promoted as public-private partnerships, are not new. What is new is the name and the way in which governments, UN agencies and NGOs are rushing into them. What is also new is the extent to which safeguards for public interest-based policy-making and scientific standard-setting are being ignored.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
“Little discussed is a type of public-for-profit sector interaction which was hitherto seen as problematic in democratic societies: a new development in the name of 'partnership' is the ready acceptance of corporate participation in public policy-making, respectively UN attendance of corporate fora. […] Business leaders have also used their close relationship with the UN to press for a distinction between 'reasonable' and 'confrontational' NGOs. They have questioned the public funding of those NGOs which business labels as confrontational.<br />
The second problem is that the term 'partnership' is heavily value-laden. It gives the impression of equality and suggests that all sides are working for a joint goal. The positive connotation of public-private partnerships is no oversight. Indeed, two other value-laden terms are usually cited as main criteria for engaging in 'partnerships' with corporations and their business associations, namely 'trust' and 'mutual benefits'. Both the name and these criteria interfere with unprejudiced evaluations of whether or not these interactions are indeed beneficial for society. The measuring stick for engaging with corporations must remain the contribution of the venture to the promotion of public interests. It cannot be a question of trading some public interests against profit for the corporate participant.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
=== Risks ===<br />
<br />
Risks so far remain “underexplored. […] The general trend towards PPPs can […] lead to censorship by and self-censorship within the UN, government or NGO counterpart and an overly optimistic depiction of transnational corporations' actual practices. It can result in 'institutional capture' in which the non-corporate partner is instrumentalised for a company's or business association's aims. Public-private partnerships risk weakening the key drivers of corporate 'responsibility', namely binding regulation, collective bargaining and more radical forms of social activism.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7993International Federation of Pharmaceutical Manufacturers and Associations2006-04-24T15:41:30Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
Furthermore, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7977International Federation of Pharmaceutical Manufacturers and Associations2006-04-24T15:25:17Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
Moreover, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the [[Global Alliance on Vaccines Initiative]] (GAVI) has US$1 billion just for vaccines and the [[Bill and Melinda Gates Foundation]] is spending well over US$6 billion on infectious diseases?” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7963International Federation of Pharmaceutical Manufacturers and Associations2006-04-24T15:14:30Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
<br />
Judith Richter says “one has to look at today's public-private ventures in light of the political developments of the past thirty years. In her presentation, she highlighted the need to analyse so-called public-private partnerships also as part of a sophisticated corporate issues management plan aimed at advancing the political and economic agenda of transnational (TNC) corporations. An unquestioning rush on the part of many governments, UN agencies and some NGOs to join such 'partnerships' may ultimately damage public interests, she argues.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
There are essential questions that have to be addressed in the discourse on ‘public-private partnerships’ (PPP)<br />
<br />
=== Money ===<br />
<br />
“The PPP discourse also does not mention that those transnational corporations that are offering donations to public institutions are often the very same corporations that have successfully lobbied for global tax restructuring. This has resulted in a redistribution of the world's wealth from the poor to the rich and the erosion of states' capacities to provide for public services.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
Moreover, attention has to be paid to the power and influence that the money involved in PPPs buys. “How much of a voice does the World Health Organization have in setting priorities for world health with its budget of approximately US$1 billion, when the Global Alliance on Vaccines Initiative (GAVI) has US$1 billion just for vaccines and the Bill and Melinda Gates Foundation is spending well over US$6 billion on infectious diseases?” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
=== Motivation ===<br />
<br />
Why are companies interested in establishing ‘partnerships’ with public services? <br />
“We cannot escape the fact that all corporations have a fiduciary (legal) duty to maximise profit for their shareholders. No matter what the rhetoric, and the often good intentions of individuals working within corporations, there has to be a financial payoff-either in the short or long-term.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item6]<br />
<br />
“Not only corporate public relations professionals but also institutions such as the World Bank have advised corporate managers to engage in 'partnerships' with reputable institutions and individuals in order to 'build trust'. [...] Close association with the UN and NGOs can, for example, enhance the reputation of corporations through 'image transfer', irrespective of their actual practices. A good image can be of advantage in a competitive market. It is also a political resource. Corporations want to be seen as 'good corporate citizens'. They know that this might well translate into enhanced political legitimacy and influence.” [http://www.haiweb.org/campaign/PPI/seminar200011.html#item3]<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7945International Federation of Pharmaceutical Manufacturers and Associations2006-04-24T14:50:39Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation]] (WHO)<br />
* [[World Trade Organisation]] (WTO)<br />
* [[World Intellectual Property Organisation]] (WIPO)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[United Nations Conference on Trade and Development]] (UNCTAD)<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
For Gill Walt, the reason for the "shift towards public-private partnerships on health is the result of increased global integration due to: <br />
* The scope and pace of goods moving across borders<br />
* The lack of geographical boundaries for infectious diseases<br />
* The increased possibility for rapid communication (Internet)<br />
* The spread of ideas<br />
* World-wide products and marketing" [http://www.haiweb.org/campaign/PPI/seminar200011.html#item2]<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=AstraZeneca&diff=7816AstraZeneca2006-04-23T18:15:37Z<p>Hmu05654: </p>
<hr />
<div>==Company Name:==<br />
<br />
<br />
'''AstraZeneca Plc'''[http://www.astrazeneca.com/]<br />
<br />
Market Capital �m: 2000: 2001: 56,334.9 FT UK 500 (2001)<br />
<br />
Turnover �m: 2001: 12,325.0 FT UK 500 (2001)<br />
<br />
==Organisations in which membership is held:== <br />
<br />
<br />
[[Sourcewatch: Public Affairs Council|Public Affairs Council]]<br />
<br />
[[Business in the Community]] [http://www.bitc.org.uk Website]<br />
<br />
*[[International Life Sciences Institute]] [http://www.ilsi.org Website]<br />
<br />
*[[Centre for European Reform]]<br />
<br />
*[[Sourcewatch:Foundation for Public Affairs|Foundation for Public Affairs]] [http://www.pac.org/fpa website]<br />
<br />
*[[Conference Board]]<br />
<br />
*[[European Council on Corporate Communications]] (Conference Board) [http://www.conference-board.org/pdf_free/314000.pdf]<br />
<br />
*[[Council of Chief Risk Officers]] (Conference Board) [http://www.conference-board.org/memberservices/councilsDetailUS.cfm?Council_ID=147]<br />
<br />
*[[European Round Table of Industrialists]] [http://www.ert.be/] <br />
<br />
*[[Science Media Centre]]<br />
<br />
*[[Royal Institute of International Affairs]]<br />
<br />
*[[International Federation of Pharmaceutical Manufacturers and Associations]]<br />
<br />
==CSR (Corporate Social Responsibility) Ventures==<br />
<br />
&#39;AstraZeneca Science Teaching Trust which in 2001 sponsored the &#39;Little Book of Experiments&#39; which was distributed to UK primary schools as part of the National year of Science. programme.<br />
<br />
In 2001, AstraZeneca&#39;s overall community spend totalled $19 million.&#39; (Source: AstraZeneca Annual Review 2001, page 23)<br />
<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-cal-00-8.asp&#39;AZ UK&#39;s CALM Programme - AstraZeneca UK&#39;s CALM Programme] is designed to promote well-being by helping employees achieve the right balance between work and leisure. The Programme aims to help people recognise signs of stress, and to provide routes of confidential support.&#39;<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-hea-01-1.asp&#39;The Balanced Living Charter] launched in 2001, developed in response to the leadership team&#39;s concern about stress-related illness and is used as a basis for action to improve the management of pressure. Its creation was intended for AstraZeneca staff working at the UK R&D sites to obtain the appropriate balance between work and home life and is intended to be used as a basis for action to improve the management of stress.&#39;<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-gl-ani-00-1.asp&#39;Reaching Out: AstraZeneca Anniversary] - to mark their first anniversary in June 2000, AstraZeneca reached out into their local communities around the world. Examples include: <br />
1) A trip to London Eye, hosted by the employees from Corporate Office in London for local schoolchildren who might otherwise not had the opportunity.<br />
2) New science and maths books were donated to two local high schools for 1st year pupils by AstraZeneca R&D in Sodertajle, Sweden.<br />
3) Over 200 employees in Portugal donated their tickets to David Copperfield&#39;s Magic Show to underprivileged children in their community, 40 children with cancer and other illnesses and 50 people with learning difficulties.<br />
4) In Argentina a taskforce was set up to co-ordinate a Respiratory Health Conference where patients, doctors and nurses from a local hospital were informed about asthma, its symptoms, causes and treatments.<br />
5) In Thailand the company made a special donation of 100,000 Baht to a scholarship fund for medical students at Mahidol University.&#39;<br />
<br />
<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-isc-00-10.asp&#39;The AstraZeneca &#39;Inspiring Science&#39; Programme for Schools] is run in conjunction with the CREST Awards Scheme in the UK, comprises a programme of project work that is enjoyable, relevant to the secondary education curriculum (ages 11-18) and designed to encourage young people&#39;s interest in science. There is a competitive element to the programme, with regional competitions and a national final. Cash prizes are offered to the schools of the students who deliver the best projects.&#39;<br />
<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-tra-00-4.asp &#39;Drivers for Change&#39;] is the name for Alderley Park site&#39;s Green Commuting project which has been operating since 1997 and is aimed at reducing &#39;single occupancy vehicles&#39; for staff travelling to work. Car sharing, improved private and public bus services and the provision of cyclist and jogger changing facilities have meant an 8% reduction in car use on site. This and a number of other projects associated with car travel by staff has won the Chief Executive&#39;s Award 2000 for Travel Safety.&#39;<br />
<br />
&#39;During 2001, AstraZeneca was included in the FTSE4Good Index and the Dow Jones Sustainability Index following independent assessment of their approach to CSR.&#39;<br />
<br />
Source: AstraZeneca Annual Review 2001, p 23.<br />
<br />
==PR and lobbying agencies==<br />
<br />
*[[Edelman]]</div>Hmu05654https://powerbase.info/index.php?title=AstraZeneca&diff=7744AstraZeneca2006-04-23T18:14:42Z<p>Hmu05654: </p>
<hr />
<div>==Company Name:==<br />
<br />
<br />
'''AstraZeneca Plc'''[http://www.astrazeneca.com/]<br />
<br />
Market Capital �m: 2000: 2001: 56,334.9 FT UK 500 (2001)<br />
<br />
Turnover �m: 2001: 12,325.0 FT UK 500 (2001)<br />
<br />
==Organisations in which membership is held:== <br />
<br />
<br />
[[Sourcewatch: Public Affairs Council|Public Affairs Council]]<br />
<br />
[[Business in the Community]] [http://www.bitc.org.uk Website]<br />
<br />
*[[International Life Sciences Institute]] [http://www.ilsi.org Website]<br />
<br />
*[[Centre for European Reform]]<br />
<br />
*[[Sourcewatch:Foundation for Public Affairs|Foundation for Public Affairs]] [http://www.pac.org/fpa website]<br />
<br />
*[[Conference Board]]<br />
<br />
*[[European Council on Corporate Communications]] (Conference Board) [http://www.conference-board.org/pdf_free/314000.pdf]<br />
<br />
*[[Council of Chief Risk Officers]] (Conference Board) [http://www.conference-board.org/memberservices/councilsDetailUS.cfm?Council_ID=147]<br />
<br />
*[[European Round Table of Industrialists]] [http://www.ert.be/] <br />
<br />
*[[Science Media Centre]]<br />
<br />
*[[Royal Institute of International Affairs]]<br />
<br />
*[[International Federation of Pharmaceutical Manufacturers & Associations]]<br />
<br />
==CSR (Corporate Social Responsibility) Ventures==<br />
<br />
&#39;AstraZeneca Science Teaching Trust which in 2001 sponsored the &#39;Little Book of Experiments&#39; which was distributed to UK primary schools as part of the National year of Science. programme.<br />
<br />
In 2001, AstraZeneca&#39;s overall community spend totalled $19 million.&#39; (Source: AstraZeneca Annual Review 2001, page 23)<br />
<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-cal-00-8.asp&#39;AZ UK&#39;s CALM Programme - AstraZeneca UK&#39;s CALM Programme] is designed to promote well-being by helping employees achieve the right balance between work and leisure. The Programme aims to help people recognise signs of stress, and to provide routes of confidential support.&#39;<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-hea-01-1.asp&#39;The Balanced Living Charter] launched in 2001, developed in response to the leadership team&#39;s concern about stress-related illness and is used as a basis for action to improve the management of pressure. Its creation was intended for AstraZeneca staff working at the UK R&D sites to obtain the appropriate balance between work and home life and is intended to be used as a basis for action to improve the management of stress.&#39;<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-gl-ani-00-1.asp&#39;Reaching Out: AstraZeneca Anniversary] - to mark their first anniversary in June 2000, AstraZeneca reached out into their local communities around the world. Examples include: <br />
1) A trip to London Eye, hosted by the employees from Corporate Office in London for local schoolchildren who might otherwise not had the opportunity.<br />
2) New science and maths books were donated to two local high schools for 1st year pupils by AstraZeneca R&D in Sodertajle, Sweden.<br />
3) Over 200 employees in Portugal donated their tickets to David Copperfield&#39;s Magic Show to underprivileged children in their community, 40 children with cancer and other illnesses and 50 people with learning difficulties.<br />
4) In Argentina a taskforce was set up to co-ordinate a Respiratory Health Conference where patients, doctors and nurses from a local hospital were informed about asthma, its symptoms, causes and treatments.<br />
5) In Thailand the company made a special donation of 100,000 Baht to a scholarship fund for medical students at Mahidol University.&#39;<br />
<br />
<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-isc-00-10.asp&#39;The AstraZeneca &#39;Inspiring Science&#39; Programme for Schools] is run in conjunction with the CREST Awards Scheme in the UK, comprises a programme of project work that is enjoyable, relevant to the secondary education curriculum (ages 11-18) and designed to encourage young people&#39;s interest in science. There is a competitive element to the programme, with regional competitions and a national final. Cash prizes are offered to the schools of the students who deliver the best projects.&#39;<br />
<br />
<br />
[http://www.astrazeneca.com/mainnav1/about/cr/s_projects/project_list/c_projects_list/project-uk-tra-00-4.asp &#39;Drivers for Change&#39;] is the name for Alderley Park site&#39;s Green Commuting project which has been operating since 1997 and is aimed at reducing &#39;single occupancy vehicles&#39; for staff travelling to work. Car sharing, improved private and public bus services and the provision of cyclist and jogger changing facilities have meant an 8% reduction in car use on site. This and a number of other projects associated with car travel by staff has won the Chief Executive&#39;s Award 2000 for Travel Safety.&#39;<br />
<br />
&#39;During 2001, AstraZeneca was included in the FTSE4Good Index and the Dow Jones Sustainability Index following independent assessment of their approach to CSR.&#39;<br />
<br />
Source: AstraZeneca Annual Review 2001, p 23.<br />
<br />
==PR and lobbying agencies==<br />
<br />
*[[Edelman]]</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7706International Federation of Pharmaceutical Manufacturers and Associations2006-04-22T18:40:58Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation (WHO)]]<br />
* [[World Trade Organisation (WTO)]]<br />
* [[World Intellectual Property Organisation (WIPO)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Why are 'public-private partnerships' problematic? ==<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7705International Federation of Pharmaceutical Manufacturers and Associations2006-04-22T17:23:45Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation (WHO)]]<br />
* [[World Trade Organisation (WTO)]]<br />
* [[World Intellectual Property Organisation (WIPO)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7704International Federation of Pharmaceutical Manufacturers and Associations2006-04-22T17:22:04Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation (WHO)]]<br />
* [[World Trade Organisation (WTO)]]<br />
* [[World Intellectual Property Organisation (WIPO)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
From the IFPMA website:<br />
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:<br />
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;<br />
* to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;<br />
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;<br />
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;<br />
* to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives.<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7703International Federation of Pharmaceutical Manufacturers and Associations2006-04-22T16:28:59Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation (WHO)]]<br />
* [[World Trade Organisation (WTO)]]<br />
* [[World Intellectual Property Organisation (WIPO)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7694International Federation of Pharmaceutical Manufacturers and Associations2006-04-22T16:25:55Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History and mission ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are: <br />
* [[World Health Organisation (WHO)]]<br />
* [[World Trade Organisation]]<br />
* [[World Intellectual Property Organisation (WIPO)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[United Nations Conference on Trade and Development (UNCTAD)]]<br />
* [[Council of Europe]]<br />
[http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Objectives ==<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7693International Federation of Pharmaceutical Manufacturers and Associations2006-04-22T16:18:18Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". <br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [http://www.ifpma.org/About_Us/about_mission.aspx]<br />
<br />
== Mission and objectives ==<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==<br />
<br />
* http://www.ifpma.org/index.aspx<br />
* http://www.haiweb.org</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7692International Federation of Pharmaceutical Manufacturers and Associations2006-04-22T16:14:59Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History ==<br />
<br />
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines.<br />
The conditions for membership of the Federation include to good manufacturing practices and acceptance of the IFPMA Code of Pharmaceutical Marketing Practices<br />
In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission.<br />
<br />
== Positions ==<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7691International Federation of Pharmaceutical Manufacturers and Associations2006-04-21T18:40:21Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]<br />
<br />
== History ==<br />
<br />
<br />
<br />
== Positions ==<br />
<br />
<br />
<br />
== Individuals ==<br />
<br />
IFPMA President <br />
<br />
* [[Dr. Daniel Vasella]], Chairman and Chief Executive Officer Novartis International AG<br />
<br />
IFPMA Vice Presidents <br />
<br />
* [[Dr. Henry A. McKinnell, Jr.]], Chairman and Chief Executive Officer Pfizer Inc.<br />
*[[Haruo Naito]], President and Chief Executive Officer Eisai Co. Ltd.<br />
<br />
[http://www.ifpma.org/About_Us/about_council.aspx]<br />
<br />
Directors <br />
<br />
* [[Dr. Harvey E. Bale, Jr.]], Director General<br />
* [[Dr. Odette Morin]], Director, Regulatory and Scientific Affairs<br />
* [[Dr. Eric Noehrenberg]], Director, International Trade and Market Policy <br />
* [[Dr. Ryoko Krause]], Director, Biologicals and Vaccines <br />
* [[Dr. Frédérique Santerre]], Health Care Systems (ad-interim)<br />
* [[Mr. Guy Willis]], Director of Communications <br />
* [[Mr. Takeshi Sano]], Japan Liaison Executive <br />
<br />
[http://www.ifpma.org/About_Us/about_sec.aspx]<br />
<br />
== Members ==<br />
<br />
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:<br />
<br />
* [[Abbott Laboratories]]<br />
* [[Akzo Nobel – Organon]]<br />
* [[Almirall-Prodesfarma]]<br />
* [[AstraZeneca]]<br />
* [[Bayer]]<br />
* [[Boehringer Ingelheim]]<br />
* [[Bristol-Myers Squibb]]<br />
* [[Chugai Pharmaceutical]]<br />
* [[Eisai]]<br />
* [[Eli Lilly]]<br />
* [[Esteve]]<br />
* [[F-Hoffmann-La Roche]]<br />
* [[Astellas Pharma Inc.]]<br />
* [[GlaxoSmithKline]]<br />
* [[Merck & Co., Inc.]]<br />
* [[Menarini S.A.]]<br />
* [[Merck KGaA]]<br />
* [[Novartis International AG]]<br />
* [[Pfizer]]<br />
* [[Sanofi-Aventis]]<br />
* [[Institut de Recherches Internationales Servier – I.R.I.S.]]<br />
* [[Sigma-Tau]]<br />
* [[Schering AG]]<br />
* [[Schering-Plough]]<br />
* [[Takeda]]<br />
* [[Wyeth]]<br />
<br />
[http://www.ifpma.org/About_Us/about_mem_americas.aspx]<br />
<br />
== External links ==</div>Hmu05654https://powerbase.info/index.php?title=EU_lobbying&diff=12320EU lobbying2006-04-21T16:18:29Z<p>Hmu05654: </p>
<hr />
<div>The European Union is increasingly at the forefront of neoliberal reforms in Europe. Much of this is taken forward as a result of the close relationship between corporate lobbyists and European civil servants. Corporate lobbyists now outnumber EC officials by a factor of about 5 to one, according to conservative estimates.<br />
<br />
==Lobbying industry organisations==<br />
<br />
*[[Association Francaise des Conseils en Affaires Publique]]<br />
*[[European Public Affairs Consultants Association]]<br />
*[[EUlobby.net]]<br />
*[[Society of European Affairs Professionals]] - SEAP<br />
<br />
<br />
==Peak Business Associations==<br />
<br />
*[[European Chemical Industry Council]] CEFIC<br />
*[[European Information, Communications and Consumer Electronics Technology Industry Associations]]<br />
*[[European Roundtable of Industrialists]] - ERT<br />
*[[European Services Forum]]<br />
*[[Trans Atlantic Business Dialogue]]<br />
*[[UNICE]]<br />
*[[International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)]]<br />
<br />
==Front Groups==<br />
<br />
*[[Bromine Science and Environment Forum]]<br />
*[[Campaign for Creativity]]<br />
*[[European Partnership for Energy and the Environment]]<br />
<br />
==Policy planning lobby groups==<br />
<br />
*[[European Corporate Governance Institute]]<br />
*[[European Parliamentary Financial Services Forum]]<br />
<br />
==Think Tanks==<br />
<br />
*[[Afidora]]<br />
*[[Brussels European and Global Economic Laboratory]]<br />
*[[Centre for the New Europe]] [http://www.cne-network.org/] <br />
*[[Civita]] [http://www.civita.no/civ.php?mod=content&id=6]<br />
*[[Copenhagen Institute]] [http://www.coin.dk/]<br />
*[[European Science and Environment Forum]]<br />
*[[Edmund Burke Foundation]] [http://www.burkestichting.nl/]<br />
*[[Studienzentrum Weikersheim]]<br />
*[[Federation of European Employers]] [http://www.fedee.com/]<br />
*[[Istituto Bruno Leoni]]<br />
*[[Libres]] [http://www.libres.org/]<br />
*[[Open Republic Institute]] [http://www.openrepublic.org/]<br />
*[http://www.realinstitutoelcano.org/ Real Instituto Elcano]<br />
*[http://www.case.com.pl CASE - the Center for Social and Economic Research]<br />
*[[Timbro]] [http://www.timbro.com/]<br />
*The [[Centre for European Policy Studies]] (CEPS)<br />
*The [[European Policy Centre]] (EPC)<br />
*[[Friends of Europe]]<br />
*[[Health Consumer Powerhouse]]<br />
*[[Institut Economique Molinari]]<br />
*[[Institut Hayek]]<br />
*[[Institut Thomas More Brussels]]<br />
*The [[International Council for Capital Formation]]<br />
*The [[International Policy Network]]<br />
*The [[Lisbon Council]]<br />
*[[New Defence Agenda]]<br />
*The [[Stockholm Network]]<br />
*[[Tech Central Station]]<br />
<br />
==Trade Press==<br />
<br />
*[[Public Affairs Newsletter]]<br />
*[[European Voice]]<br />
*[[E! Sharp]]<br />
<br />
==Academic connections==<br />
<br />
*[[European Centre for Public Affairs]]<br />
*[[Justin Greenwood]]<br />
*[[Robin Pedler]]<br />
*[[Tom Spencer]]<br />
<br />
==Foundations==<br />
<br />
*[[Friedrich Ebert Foundation]]<br />
<br />
==Key lobbyists==<br />
<br />
*[[Paul Adamson]]<br />
*[[Stanley Crossick]]<br />
*[[Elaine Cruikshanks]]<br />
*[[David Earnshaw]]<br />
*[[Christian De Fouloy]]<br />
*[[Gerry Wade]]<br />
<br />
==EU lobbying consultancies==<br />
<br />
*[[Bruce Naughton Wade]]<br />
*[[Burson Marstellar]]<br />
*[[Edelman]]<br />
*[[EPPA]]<br />
*[[Houston Consulting]]<br />
<br />
==Further reading==<br />
<br />
BBC Radio Four, File On Four, documentary on EU lobbying <br />
issues (broadcast 22 November 2005) Transcript: http://news.bbc.co.uk/nol/shared/bsp/hi/pdfs/22_11_05_lobbying.pdf</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7627International Federation of Pharmaceutical Manufacturers and Associations2006-04-20T12:00:24Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [http://www.ifpma.org/index.aspx] <br />
It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [http://www.haiweb.org/campaign/PPI/seminar200011.html#ftn2]</div>Hmu05654https://powerbase.info/index.php?title=International_Federation_of_Pharmaceutical_Manufacturers_and_Associations&diff=7577International Federation of Pharmaceutical Manufacturers and Associations2006-04-20T11:51:54Z<p>Hmu05654: </p>
<hr />
<div>The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries".</div>Hmu05654https://powerbase.info/index.php?title=EU_lobbying&diff=7618EU lobbying2006-04-20T11:48:37Z<p>Hmu05654: </p>
<hr />
<div>The European Union is increasingly at the forefront of neoliberal reforms in Europe. Much of this is taken forward as a result of the close relationship between corporate lobbyists and European civil servants. Corporate lobbyists now outnumber EC officials by a factor of about 5 to one, according to conservative estimates.<br />
<br />
==Lobbying industry organisations==<br />
<br />
*[[Association Francaise des Conseils en Affaires Publique]]<br />
*[[European Public Affairs Consultants Association]]<br />
*[[EUlobby.net]]<br />
*[[Society of European Affairs Professionals]] - SEAP<br />
*[[International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)]]<br />
<br />
==Peak Business Associations==<br />
<br />
*[[European Chemical Industry Council]] CEFIC<br />
*[[European Information, Communications and Consumer Electronics Technology Industry Associations]]<br />
*[[European Roundtable of Industrialists]] - ERT<br />
*[[European Services Forum]]<br />
*[[Trans Atlantic Business Dialogue]]<br />
*[[UNICE]]<br />
<br />
==Front Groups==<br />
<br />
*[[Bromine Science and Environment Forum]]<br />
*[[Campaign for Creativity]]<br />
*[[European Partnership for Energy and the Environment]]<br />
<br />
==Policy planning lobby groups==<br />
<br />
*[[European Corporate Governance Institute]]<br />
*[[European Parliamentary Financial Services Forum]]<br />
<br />
==Think Tanks==<br />
<br />
*[[Afidora]]<br />
*[[Brussels European and Global Economic Laboratory]]<br />
*[[Centre for the New Europe]] [http://www.cne-network.org/] <br />
*[[Civita]] [http://www.civita.no/civ.php?mod=content&id=6]<br />
*[[Copenhagen Institute]] [http://www.coin.dk/]<br />
*[[European Science and Environment Forum]]<br />
*[[Edmund Burke Foundation]] [http://www.burkestichting.nl/]<br />
*[[Studienzentrum Weikersheim]]<br />
*[[Federation of European Employers]] [http://www.fedee.com/]<br />
*[[Istituto Bruno Leoni]]<br />
*[[Libres]] [http://www.libres.org/]<br />
*[[Open Republic Institute]] [http://www.openrepublic.org/]<br />
*[http://www.realinstitutoelcano.org/ Real Instituto Elcano]<br />
*[http://www.case.com.pl CASE - the Center for Social and Economic Research]<br />
*[[Timbro]] [http://www.timbro.com/]<br />
*The [[Centre for European Policy Studies]] (CEPS)<br />
*The [[European Policy Centre]] (EPC)<br />
*[[Friends of Europe]]<br />
*[[Health Consumer Powerhouse]]<br />
*[[Institut Economique Molinari]]<br />
*[[Institut Hayek]]<br />
*[[Institut Thomas More Brussels]]<br />
*The [[International Council for Capital Formation]]<br />
*The [[International Policy Network]]<br />
*The [[Lisbon Council]]<br />
*[[New Defence Agenda]]<br />
*The [[Stockholm Network]]<br />
*[[Tech Central Station]]<br />
<br />
==Trade Press==<br />
<br />
*[[Public Affairs Newsletter]]<br />
*[[European Voice]]<br />
*[[E! Sharp]]<br />
<br />
==Academic connections==<br />
<br />
*[[European Centre for Public Affairs]]<br />
*[[Justin Greenwood]]<br />
*[[Robin Pedler]]<br />
*[[Tom Spencer]]<br />
<br />
==Foundations==<br />
<br />
*[[Friedrich Ebert Foundation]]<br />
<br />
==Key lobbyists==<br />
<br />
*[[Paul Adamson]]<br />
*[[Stanley Crossick]]<br />
*[[Elaine Cruikshanks]]<br />
*[[David Earnshaw]]<br />
*[[Christian De Fouloy]]<br />
*[[Gerry Wade]]<br />
<br />
==EU lobbying consultancies==<br />
<br />
*[[Bruce Naughton Wade]]<br />
*[[Burson Marstellar]]<br />
*[[Edelman]]<br />
*[[EPPA]]<br />
*[[Houston Consulting]]<br />
<br />
==Further reading==<br />
<br />
BBC Radio Four, File On Four, documentary on EU lobbying <br />
issues (broadcast 22 November 2005) Transcript: http://news.bbc.co.uk/nol/shared/bsp/hi/pdfs/22_11_05_lobbying.pdf</div>Hmu05654